These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32842794)

  • 1. A clinical review of the t:slim X2 insulin pump.
    Berget C; Lange S; Messer L; Forlenza GP
    Expert Opin Drug Deliv; 2020 Dec; 17(12):1675-1687. PubMed ID: 32842794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update.
    Pinsker JE; Leas S; Müller L; Habif S
    Endocr Pract; 2020 Jul; 26(7):714-721. PubMed ID: 33471639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    BMC Med; 2024 Apr; 22(1):175. PubMed ID: 38659016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 6. Real world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus-a National Health Service pilot initiative in England.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    Diabet Med; 2023 Feb; 40(2):e15015. PubMed ID: 36424877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
    Rizzi A; Tartaglione L; Lucaccini Paoli L; Leo ML; Popolla V; Viti L; Barberio A; Di Leo M; Pontecorvi A; Pitocco D
    Diabetes Obes Metab; 2024 Sep; 26(9):4078-4086. PubMed ID: 39010292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid closed-loop therapy: Where are we in 2021?
    Leelarathna L; Choudhary P; Wilmot EG; Lumb A; Street T; Kar P; Ng SM
    Diabetes Obes Metab; 2021 Mar; 23(3):655-660. PubMed ID: 33269551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commercial hybrid closed-loop systems available for a patient with type 1 diabetes in 2022.
    Seget S; Tekielak A; Rusak E; Jarosz-Chobot P
    Pediatr Endocrinol Diabetes Metab; 2023; 29(1):30-36. PubMed ID: 37218723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology.
    Hood KK; Schneider-Utaka AK; Reed ZW; Buckingham BA; Cobry E; DeBoer MD; Ekhlaspour L; Schoelwer M; Paul Wadwa R; Lum J; Kollman C; Beck RW; Breton MD;
    Diabetes Res Clin Pract; 2024 Feb; 208():111114. PubMed ID: 38278493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypoglycemia prevention via pump attenuation and red-yellow-green "traffic" lights using continuous glucose monitoring and insulin pump data.
    Hughes CS; Patek SD; Breton MD; Kovatchev BP
    J Diabetes Sci Technol; 2010 Sep; 4(5):1146-55. PubMed ID: 20920434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.
    Scully KJ; Palani G; Zheng H; Moheet A; Putman MS
    Diabetes Technol Ther; 2022 Jun; 24(6):446-452. PubMed ID: 35020476
    [No Abstract]   [Full Text] [Related]  

  • 14. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes.
    Levy CJ; Bailey R; Laffel LM; Forlenza G; DiMeglio LA; Hughes MS; Brown SA; Aleppo G; Bhargava A; Shah VN; Clements MA; Kipnes M; Bruggeman B; Daniels M; Rodriguez H; Calhoun P; Lum JW; Sasson-Katchalski R; Pinsker JE; Pollom R; Beck RW;
    Diabetes Technol Ther; 2024 Sep; 26(9):652-660. PubMed ID: 38696672
    [No Abstract]   [Full Text] [Related]  

  • 15. The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis.
    Pease A; Lo C; Earnest A; Kiriakova V; Liew D; Zoungas S
    Diabetes Technol Ther; 2020 May; 22(5):411-421. PubMed ID: 31904262
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
    Rodbard D
    Diabetes Technol Ther; 2017 Jun; 19(S3):S25-S37. PubMed ID: 28585879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care.
    Messer LH; Breton MD
    Diabetes Technol Ther; 2023 Dec; 25(12):877-882. PubMed ID: 37751154
    [No Abstract]   [Full Text] [Related]  

  • 18. Closed-loop system in the management of diabetes: past, present, and future.
    Shah VN; Shoskes A; Tawfik B; Garg SK
    Diabetes Technol Ther; 2014 Aug; 16(8):477-90. PubMed ID: 25072271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort.
    Müller L; Habif S; Leas S; Aronoff-Spencer E
    Diabetes Technol Ther; 2019 Sep; 21(9):478-484. PubMed ID: 31329468
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes.
    Calhoun PM; Buckingham BA; Maahs DM; Hramiak I; Wilson DM; Aye T; Clinton P; Chase P; Messer L; Kollman C; Beck RW; Lum J;
    J Diabetes Sci Technol; 2016 Nov; 10(6):1216-1221. PubMed ID: 27207890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.